|

Positive vaccine development but rising coronavirus numbers now

Market overview

Positive vaccine development but rising coronavirus numbers now

COVID-19 numbers have risen sharply in Europe and the US, leading to the imposition of new restrictions and partial lockdowns that are set to weigh on economic activity in the months to come. Recent Phase 3 vaccine trials are showing promising results and markets have now started to price out some of the tail risks of subdued activity long into 2021. Despite recent positive vaccine news, a full rollout of vaccine programmes is still some way off and current restrictions are set to weigh on demand in coming months. In our view, the coming months will be a balancing act between bad numbers on COVID-19 and growth and (one hopes) more positive news on vaccine trials.

Fading risks from US politics and EU budget, but Brexit still lurk

The outcome of the recent US election, with Joe Biden elected President and a Democratic House, has led political uncertainties about China, trade, the US's COVID-19 handling and so on to fade a bit but uncertainty remains about who will get the majority in the Senate. It all boils down to two special Senate run-offs in Georgia, due to take place on 5 January. With a current leaning towards a Republican majority, incoming president Joe Biden may see himself a lame duck with a divided Congress when taking office in January, limiting the hopes of large fiscal easing in 2021, big infrastructure plans, tax hikes and so on. There has been progress on the EU budget but there are still significant hurdles left for the recovery fund. Further discussion still looms on the terms and conditions of the recovery and resilience facility and the ratification in national parliaments could prove a hurdle, with Hungary already threatening to veto the package. Notable among the remaining uncertainties is the Brexit process, which has the potential to rock the boat around New Year. However, we expect a simple free-trade agreement within coming weeks.

Market relief from fading uncertainties

Market relief on the back of the US election led risky assets to perform and volatility to decrease notably. Recent positive COVID-19 vaccine news adds fuel to the fire, leading more classic sectors such as banks and industry (EU) to outperform growth sectors such as tech (US),but current negative COVID-19 pandemic developments cap the topside for now. EUR/USD has moved towards 1.19 on the back of the US election but grinded marginally lower again despite positive vaccine developments and sector rotation. A weakening USD and fading short-term uncertainty have been tailwinds to emerging market FX, Scandies and cyclicals lately but such FX moves may not extend without further direction set by monetary or fiscal policy and/or sustained signs of global economic recovery.

USD weak for now but remains long-term winner

We see EUR/USD around 1.20 in 3M but longer term we believe the USD will still be 'the winner' and we forecast 1.16 in 12M. We target EUR/SEK around 10.30 in 1-3M before a move towards 10.10 in 6-12M on recovery tailwinds. Meanwhile, we see EUR/NOK on a downward trajectory supported by the external environment and strong domestics and project 10.40 in 12M. We expect EUR/GBP to go towards 0.86 on a resolved Brexit near term.

Oil market can see light at the end of the tunnel

Positive news on the COVID-19 vaccine front has brightened the outlook for oil prices. However, on the way to a rollout of vaccines and full reopening of economies, the oil market is likely to see new lockdowns curbing demand and inventories are still elevated. In addition, eventual normalisation of OPEC+ production levels and slowly rising shale oil output are headwinds to the oil market too. Thus, we expect oil prices to stay range-bound for the rest of 2020 but on a slowly upward path over 2021.

Author

Danske Research Team

Danske Research Team

Danske Bank A/S

Research is part of Danske Bank Markets and operate as Danske Bank's research department. The department monitors financial markets and economic trends of relevance to Danske Bank Markets and its clients.

More from Danske Research Team
Share:

Editor's Picks

EUR/USD stays defensive below 1.1900 as USD recovers

EUR/USD trades in negative territory for the third consecutive day, below 1.1900 in the European session on Thursday. A modest rebound in the US Dollar is weighing on the pair, despite an upbeat market mood. Traders keep an eye on the US weekly Initial Jobless Claims data for further trading impetus. 

GBP/USD holds above 1.3600 after UK data dump

\GBP/USD moves little while holding above 1.3600 in the European session on Thursday, following the release of the UK Q4 preliminary GDP, which showed a 0.1% growth against a 0.2% increase expected. The UK industrial sector activity deteriorated in Decembert, keeping the downward pressure intact on the Pound Sterling. 

Gold sticks to modest intraday losses as reduced March Fed rate cut bets underpin USD

Gold languishes near the lower end of its daily range heading into the European session on Thursday. The precious metal, however, lacks follow-through selling amid mixed cues and currently trades above the $5,050 level, well within striking distance of a nearly two-week low touched the previous day.

Cardano eyes short-term rebound as derivatives sentiment improves

Cardano (ADA) is trading at $0.257 at the time of writing on Thursday, after slipping more than 4% so far this week. Derivatives sentiment improves as ADA’s funding rates turn positive alongside rising long bets among traders.

The market trades the path not the past

The payroll number did not just beat. It reset the tone. 130,000 vs. 65,000 expected, with a 35,000 whisper. 79 of 80 economists leaning the wrong way. Unemployment and underemployment are edging lower. For all the statistical fog around birth-death adjustments and seasonal quirks, the core message was unmistakable. The labour market is not cracking.

Sonic Labs’ vertical integration fuels recovery in S token

Sonic, previously Fantom (FTM), is extending its recovery trade at $0.048 at the time of writing, after rebounding by over 12% the previous day. The recovery thesis’ strengths lie in the optimism surrounding Sonic Labs’ Wednesday announcement to shift to a vertically integrated model, aimed at boosting S token utility.